Prima appoints head of investor relations
21 January, 2015 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has named Stewart Roberts its head of investor relations, as the company seeks to build on the acquisition of Immutep by attracting new shareholders.
Monash, Janssen-Cilag tackle autoimmune diseases
14 January, 2015 by Dylan Bushell-EmblingMonash University has entered a collaborative research partnership with Janssen-Cilag to explore potential new treatments for autoimmune diseases including rheumatoid arthritis.
Imugene draws up protocol for HER-Vaxx trial
13 January, 2015 by Dylan Bushell-EmblingImugene (ASX:IMU) has drawn up the protocol for a phase Ib/II trial of HER-Vaxx in gastric cancer and appointed a nonclinical CRO to help guide the IND process for the drug.
Sirtex completes recruitment for SIR-Spheres trial
09 January, 2015 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) has now recruited over 1000 patients for its three concurrent trials of its liver cancer treatment SIR-Spheres microspheres.
Sienna secures first deal for SCD-A7
08 January, 2015 by Dylan Bushell-EmblingSienna Cancer Diagnostics has won the first commercial agreement covering the bladder cancer screening technology based on its SCD-A7 antibody.
Novogen's TRXE-009 kills melanoma in lab trial
17 December, 2014 by Dylan Bushell-EmblingShares in Novogen (ASX:NRT) surged on Tuesday after the company revealed that its TRXE-009 candidate was highly active against a second target - melanoma - during lab studies.
Potential hepatitis B cure hits trial stage
16 December, 2014 by Dylan Bushell-EmblingThe Walter and Eliza Hall Institute and partner TetraLogic Pharmaceuticals have commenced a phase I/IIa trial of a new drug showing promise as a cure for hepatitis B.
Plan B and the MRFF
11 December, 2014The federal government has revised its GP co-payment plan along with the funding mechanism for the proposed Medical Research Future Fund.
Imugene completes $3.5m capital raising
10 December, 2014 by Dylan Bushell-EmblingImugene (ASX:IMU) has completed a second placement and SPP to take the total value of its capital raising to $3.5m. Proceeds will be used in part to fund HER-Vaxx trials in gastric cancer.
Malaria on the decline
10 December, 2014Good news: the number of people dying from malaria has fallen dramatically since 2000, according to the World Malaria Report 2014.
Biotron completes recruitment for BIT225 trial
04 December, 2014 by Dylan Bushell-EmblingBiotron (ASX:BIT) has enrolled all 60 patients for a Thai phase II trial of BIT225 in HCV genotypes 1 or 3.
New brain cancer treatment on trial
04 December, 2014Collaborative research carried out for more than a decade will be funnelled into a clinical trial on a treatment for brain cancer.
Imugene to divest drug delivery platform
02 December, 2014 by Dylan Bushell-EmblingImugene has announced plans to divest its drug delivery platform linguet and revealed more promising preclinical data from its HER-Vaxx immuno-oncology program.
Virax appoints three new board members
01 December, 2014 by Dylan Bushell-EmblingVirax (ASX:VHL) has named a new non-executive chairman and two new non-executive directors to help support the clinical development of its oncology portfolio.
Novogen identifies lead anti-tropomyosin drug
24 November, 2014 by Dylan Bushell-EmblingNovogen (ASX:NRT) has selected the lead candidate from its family of drugs designed to complement existing chemotherapies by targeting a different part of a cancer's cytoskeleton.
